Caveolae, caveolin, and cavins: Potential targets for the treatment of cardiac disease

Annals of Medicine

Volumn 44, Issue 6, 2012, Pages 530-541

  Das, Manika ^a   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Caveolae; Caveolin; Cavins; Heart; Lipid raft

Indexed keywords

CAVEOLIN; CAVIN 1; CAVIN 2; CAVIN 3; CAVIN 4; CAVIN DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; CAVEOLA; CELL ORGANELLE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CAVEOLAE; CAVEOLINS; DISEASE MODELS, ANIMAL; HEART DISEASES; HUMANS; MICE;

EID: 84859638403     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.577445     Document Type: Review

References (112)

1. Brown CM, Petersen NO. An image correlation analysis of the distribution of clathrin associated adaptor protein (AP-2) at the plasma membrane. J Cell Sci. 1998;111:271-81. (Pubitemid 28064151)
2. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569-72. (Pubitemid 27248754)
3. Echarri O, Muriel O, Del Pozo MA. Intracellular trafficking of raft/caveolae domains: insights from integrin signaling. Semin Cell Dev Biol. 2007;18:627-37. (Pubitemid 350026428)
4. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett. 2007;581:2098-104. (Pubitemid 46709907)
5. Palade GE. An electron microscope study of the mitochondrial structure. J Histochem Cytochem. 1953;1:188-211.
6. Palade GE, Bruns RR. Structural modulations of plasmalemmal vesicles. J Cell Biol. 1968;37:633-49.
7. Simionescu M, Simionescu N, Palade GE. Segmental differentiations of cell junctions in the vascular endothelium. The microvasculature. J Cell Biol. 1975;67:863-85.
8. Thorn H, Stenkula KG, Karlsson, Ortegren MU, Nystrom FH, Gustavsson J, et al. Cell surface orifices of caveolae and localization of caveolin to the necks of caveolae in adipocytes. Mol Biol Cell. 2003;14:3967-76. (Pubitemid 37186301)
9. Guillot FL, Audus KL, Raub TJ. Fluid-phase endocytosis by primary cultures of bovine brain microvessel endothelial cell monolayers. Microvasc Res. 1990;39:1-14. (Pubitemid 20080122)
10. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA. 1995;92:10339-43.
11. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673-82.
12. Kurzchalia TV, Dupree P, Parton RG, Kellner R, Virta H, et al. VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol. 1992;118:1003-14.
13. Cho WJ, Chow AK, Schulz R, Daniel EE. Matrix metalloproteinase-2, caveolins, focal adhesion kinase and c-Kit in cells of the mouse myocardium. J Cell Mol Med. 2007;11:1069-86. (Pubitemid 350037049)
14. Cho WJ, Chow AK, Schulz R, Daniel EE. Caveolin-1 exists and may function in cardiomyocytes. Can J Physiol Pharmacol. 2010;88:73-6.
15. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, et al. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol. 2007;42:896-901. (Pubitemid 46527597)
16. Chow AK, Daniel EE, Schulz R. Cardiac function is not significantly diminished in hearts isolated from young caveolin-1 knockout mice. Am J Physiol. 2010;299:H1183-9.
17. Williams TM, Lisanti MP. The caveolin genes: from cell biology to medicine. Ann Med. 2004;36:584-95. (Pubitemid 40051435)
18. Monier S, Dietzen DJ, Hastings WR, Lublin DM, Kurzchalia TV, et al. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell. 1995;6:911-27.
19. Tagawa A, Mezzacasa A, Hayer A, Longalti A, Pelkmans L, Helenlus A, et al. Assembly and trafficking of caveolar domains in the cell: caveolae as stable, cargo-triggered, vesicular transporters. J Cell Biol. 2005;170:769-79. (Pubitemid 41242109)
20. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, et al. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem. 1999;274:25718-25.
21. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP, et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol. 2002;161:1357-69.
22. Mogelsvang S, Marsh BJ, Ladinsky MS, Howell KE. Predicting function from structure: 3D structure studies of the mammalian Golgi complex. Traffic. 2004;5:338-45. (Pubitemid 38660200)
23. Jansa P, Mason SW, Hoffman RV, Grumnt I, et al. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. EMBO J. 1998;17:2855-64. (Pubitemid 28227132)
24. Leary DJ, Huang S. Regulation of ribosome biogenesis within the nucleolus. FEBS Lett. 2001;509:145-50. (Pubitemid 34015932)
25. Grummt I. Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog Nucleic Acid Res Mol Biol. 1999;62:109-54.
26. Jansa P, Grummt I. Mechanism of transcription termination: PTRF interacts with the largest subunit of RNA polymerase I and dissociates paused transcription complexes from yeast and mouse. Mol Gen Genet. 1999;262:508-14. (Pubitemid 29535293)
27. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem. 2008;283:4314-22.
28. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factor. Proc Natl Acad Sci USA. 2003;100:5813-8. (Pubitemid 36576890)
29. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J. Cell type and tissue specific expression of cavelin-2. Caveolin-1 and 2 co-localize and form a stable heterooligomeric complex in vivo. J Biol Chem. 1997;272:29337-46. (Pubitemid 27498228)
30. Liu L, Brown D, McKee M, Lebrasseur NK, Yang D, Albrecht KH. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia and glucose tolerance. Cell Metab. 2008;8:310-7.
31. Hill MM, Bastiani M, Luetterforst R, Kirkham M, Nixon SJ. PTRF-cavin, a conserved cystolic protein required for caveolae formation and function. Cell. 2008;132:113-24.
32. Burgener R, Wolf M, Ganz T, Baggiolini M. Purification and characterization of a major phosphatidylserine-binding phosphoprotein from human platelets. Biochem J. 1990;269:729-34. (Pubitemid 20236084)
33. Mineo C, Ying YS, Chapline C, Jaken S, Anderson RG, et al. Targeting of protein kinase C alpha to caveo lae. J Cell Biol. 1998;141:601-10. (Pubitemid 28217907)
34. Gustincich S, Sand S, Schneider C. Serum deprivation response gene is induced by serum starvation but not by contact inhibition. Cell Growth Differ. 1993;4:753-60.
35. Gustincich S, Vatta P, Goruppi S, Wolf M, Saccone S, Della Valle G, et al. The human serum deprivation response gene (SDPR) maps to 2q32-q33 and codes for a phosphatidylserinebinding protein. Genomics. 1999;57:120-9. (Pubitemid 29187944)
36. Hansen CG, Bright NA, Howard G, Nichols BJ. SDPR induces membrane curvature and functions in the formation of caveolae. Nat Cell Biol. 2009;11:807-14.
37. Izumi Y, Hirai S, Tamai Y, Fujise-Matsuoka A, Nishimura Y, Ohno S. A protein kinase C delta binding protein SRBC whose expression is induced by serum deprivation. J Biol Chem. 1997;272:7381-9. (Pubitemid 27166449)
38. Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y. Inactivation of human SRBC, located within the 11p15.5p 15.4 tumor suppressor region, in breast and lung cancer. Cancer Res. 2001;61:7943-9. (Pubitemid 33049385)
39. McMahon KA, Zajicek H, Li WP, Peyton MJ, Minna JD, Hernandez VJ. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009;28:1001-15.
40. Ogata T, Ueyama T, Isodono K, Tagawa M, Takehara N, Kawashima T. MURC, a muscle restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbance. Mol Cell Biol. 2008;28:3424-36. (Pubitemid 351657104)
41. Tagawa M, Ueyama T, Ogata T, Takehara N, Nakajima N, Isodono K. MURC, a muscle restricted copiled protein, is involved in the regulation of skeletal myogenesis. Am J Physiol. 2008;295:C490-8. (Pubitemid 352755772)
42. Bastiani M, Liu L, Hill MM, Jedrychowski MP, Nixon SJ, Lo HP. MURC/cavin-4 and cavin family members form tissue specific caveolar complex. J Cell Biol. 2009;185:1259-73.
43. Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res. 2004;94:1408-17. (Pubitemid 38780313)
44. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008;48:359-91. (Pubitemid 351738158)
45. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2003;284:C457-74. (Pubitemid 36120083)
46. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J. Caveolin-3 knockout mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002;277:38988-97. (Pubitemid 35154765)
47. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M. Caveolin 1/3 double knockout mice are viable but lack both muscle and non-muscle caveolae and develop a severe cardiomyopathic phenotype. Am J Pathol. 2002;160:2207-17. (Pubitemid 34663411)
48. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ, et al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med. 2007;204:2373-82. (Pubitemid 47529323)
49. Wunderlich C, Schober K, Lange SA, Drab M, Braundullaens RC, Kesper P, et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun. 2006;340:702-8. (Pubitemid 43021803)
50. Capozza F, Cohen AW, Cheung MW, Sotgia F, Fchupert W, Battista M, et al. Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells. Am J Physiol Cell Physiol. 2005;288:C677-91. (Pubitemid 40229497)
51. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996;271:15160-5. (Pubitemid 26197582)
52. Crosbie RH, Yamada H, Venzke DP, Lisanti MP, Campbell KP, et al. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. FEBS Lett. 1998;427:279-82. (Pubitemid 28225074)
53. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, Macioee P, et al. Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan. Identification of a central WWlike domain within caveolin family members. J Biol Chem. 2000;275:38048-58. (Pubitemid 32004928)
54. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem. 1996;271:27237-40. (Pubitemid 26367273)
55. Smythe GM, Eby JC, Disatnik MH, Rando T. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci. 2003;116:4739-49. (Pubitemid 37541217)
56. Sotgia F, Bonuccelli G, Minetti C, Woodman Se, Capozza T, Kemp RG, et al. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. Am J Pathol. 2003;163:2619-34. (Pubitemid 37466502)
57. Galbiati F, Volonte D, Engelman JA, Scherer PE, Lisanti MP. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem. 1999;274:30315-21.
58. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998;18:365-8. (Pubitemid 28158166)
59. Carbone I, Bruno C, Sotgia F, Bado M, Broda P, Masetti E, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology. 2000;54:1373-6. (Pubitemid 30174063)
60. Galbiati F, Razani B, Lisanti MP. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med. 2001;7:435-41. (Pubitemid 32964157)
61. Fulizio L, Nascimbeni AC, Fanin M, Piluso G, Polinato L, Nigro V, et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat. 2005;25:82-9. (Pubitemid 40075917)
62. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114:2104-12. (Pubitemid 44747890)
63. O'Connell KM, Martens JR, Tamkun MM. Localization of ion channels to lipid Raft domains within the cardiovascular system. Trends Cardiovasc Med. 2004;14:37-42. (Pubitemid 38340844)
64. Maguy A, Hebert TE, Nattel S. Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc Res. 2006;69:798-807. (Pubitemid 43227978)
65. Wang XL, Ye D, Peterson TE, Cao S, Shah VH, Katusic ZS, et al. Caveolae targeting and regulation of large conductance Ca (2+)-activated K+ channels in vascular endothelial cells. J Biol Chem. 2005;280:11656-64. (Pubitemid 40418480)
66. Fujimoto T, Miyawaki A, Mikoshiba K. Inositol 1, 4, 5-trisphosphate receptor-like protein in plasmalemma caveolae is linked to actin filaments. J Cell Sci. 1995;108(Pt. 1):7-15.
67. Lohn M, Furstenau M, Sagach V, Elger M, Schulze W, Luft FC, et al. Ignition of calcium sparks in arterial and cardiac muscle through caveolae. Circ Res. 2000;87:1034-9.
68. Kwiatek AM, Minshall RD, Cool DR, Skidgel RA, Malik AB, Tiruppathi C. Caveolin-1 regulates store-operated Ca2+ influx by binding of its scaffolding domain to transient receptor potential channel-1 in endothelial cells. Mol Pharmacol. 2006;70:1174-83. (Pubitemid 44435968)
69. Bergdahl A, Gomez MF, Dreja K, Gomez MF, Dreja K, Xu SE, et al. Cholesterol depletion impairs vascular reactivity to endothelin-1 by reducing store-operated Ca2+ entry dependent on TRPC1. Circ Res. 2003;93:839-47. (Pubitemid 37363058)
70. Fagan KA, Smith KE, Cooper DM. Regulation of the Ca2+-inhibitable adenylyl cyclase type VI by capacitative Ca2+ entry requires localization in cholesterol-rich domains. J Biol Chem. 2000;275:26530-7.
71. Martens JR, Sakamoto N, Sullivan SA, Grobaski TD, Tamkun MM. Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations. Targeting of Kv1.5 to caveolae. J Biol Chem. 2001;276:8409-14.
72. Graf GA, Matveev SV, Smart EJ. Class B scavenger receptors, caveolae and cholesterol homeostasis. Trends Cardiovasc Med. 1999;9:221-5.
73. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512-9.
74. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethyl glutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113-8. (Pubitemid 32050445)
75. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation. 2003;107:2480-6. (Pubitemid 36605232)
76. Zhu Y, Liao HL, Wang N, Yuan Y, Ma KS, Verna L, et al. Lipoprotein promotes caveolin-1 and Ras translocation to caveolae: role of cholesterol in endothelial signaling. Arterioscler Thromb Vasc Biol. 2000;20:2465-70.
77. Kincer JF, Uittenbogaard A, Dressman J, Guerin TM, Febbraio M, Guo L, et al. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase mediated vascular dysfunction. J Biol Chem. 2002;277:23525-33. (Pubitemid 34952188)
78. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139-48. (Pubitemid 23326093)
79. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 1994;23:833-43. (Pubitemid 24090867)
80. Dorahy DJ, Lincz LF, Meldrum CJ, Burns GF. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J. 1996;319:67-72. (Pubitemid 26394740)
81. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest. 1999;103:897-905. (Pubitemid 29152636)
82. Febbraio M, Podrez EA, Smith JD, Schmitt D, Silverstein RL, Hazen SL, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-56. (Pubitemid 30217689)
83. Podrez EA, Febbraio M, Sheibani N, Shelbani N, Hoff HF. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095-108. (Pubitemid 30217694)
84. Ziche M, Morbidelli L, Choudhur Ri, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-34. (Pubitemid 27259809)
85. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta SP, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247:495-504. (Pubitemid 29394787)
86. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res. 1999;253:117-30.
87. Feng Y, Venema VJ, Venema RC, Tsai N, Behzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci. 1999;40:157-67. (Pubitemid 29029584)
88. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003;14:334-47. (Pubitemid 36106041)
89. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001;89:866-73. (Pubitemid 34627891)
90. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J. 2000;351:257-64.
91. Ju H, Venema VJ, Marrero MB, Venema RC. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem. 1998;273:24025-9. (Pubitemid 28435743)
92. Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol. 1999;11:737-44.
93. Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998;12:667-78. (Pubitemid 28134299)
94. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998;94:625-34. (Pubitemid 28427581)
95. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999;144:1285-94. (Pubitemid 29157305)
96. Griffoni C, Spisni E, Santi S, Riccio M, Guarnieri T, Tomasi V. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 2000;276:756-61.
97. Woodman SE, Ashton AW, Schubert W, Lee H, Williams T, Medina FA, et al. Caveolin-1 knock-out mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol. 2003;162:2059-68. (Pubitemid 36613061)
98. Diwan A, Dorn GW. Decompensation of cardiac hypertrophy: cellular mechanism and novel therapeutic target. Physiology. 2007;22:56-64.
99. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, et al. Cardiac hypertrophy is not a required compensatory response to short term pressure overload. Circulation. 2000;101:2863-9. (Pubitemid 30396019)
100. Sano M, Schneider MD. Still stressed out but doing fine: normalization of wall stress is superfluous to maintain cardiac function in chronic pressure overload. Circulation. 2002;105:8-10. (Pubitemid 34049134)
101. Koga A, Oka N, Kikuchi T, Miyazaki H, Kato S, Imaizumi T. Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension. 2003;42:213-9. (Pubitemid 36944599)
102. Fujita T, Otsu K, Oshikawa J, Hori H, Kitamura H, Ito T, et al. Caveolin-3 inhibits growth signal in cardiac myoblasts in a Ca2+-dependent manner. J Cell Mol Med. 2006;10:216-24. (Pubitemid 44874303)
103. De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, et al. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magn Reson Imaging. 2005;23:61-8. (Pubitemid 40269952)
104. Ohsawa Y, Toko H, Katsura M, Morimoto K, Yamada H, Ichikawa Y, et al. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Hum Mol Genet. 2004;13:151-7. (Pubitemid 38111353)
105. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res. 2006;69:788-97. (Pubitemid 43227977)
106. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem. 1997;272:25437-40. (Pubitemid 27438846)
107. Bolli R. The late phase of preconditioning. Circ Res. 2000;87:972-83.
108. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1131-51.
109. Ballard-Croft C, Locklar AC, Kristo G, Lasley RD. Regional myocardial ischemia-induced activation of MAPKs is associated with subcellular redistribution of caveolin and cholesterol. Am J Physiol Heart Circ Physiol. 2006;291:H658-67. (Pubitemid 44175071)
110. Das M, Gherghiceanu M, Lekli I, Mukherjee S, Popescu LM, Das DK. Essential role of lipid raft in ischemic preconditioning. Cell Physiol Biochem. 2008;21:325-34. (Pubitemid 351591424)
111. Patel HH, Tsutsumi YM, Head BP, Niesman IR, Jennings M. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J. 2007;21:1565-74. (Pubitemid 46684858)
112. Das M, Cui J, Das DK. Generation of survival signal by differential interaction of p38MAPKalpha and p38MAPKbeta with caveolin-1 and caveolin-3 in the adapted heart. J Mol Cell Cardiol. 2007;42:206-13. (Pubitemid 44958617)